Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00501345 · ClinicalTrials.gov registry record · Phase 3
Aspirin in Patients With Myocardial Infarction and Thrombocytopenia
A Phase 3 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 3
- Development phase
- 5
- Enrollment target
NCT00501345: Clinical Trial Phase 3 study, sponsored by M.D. Anderson Cancer Center.
NCT00501345 is a Phase 3 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00501345, a Phase 3 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 5 participants
- Enrollment target
Study Summary
Primary Objective: To determine the risk of bleeding from ASA therapy in thrombocytopenic patients who develop Acute Coronary Syndrome (ACS), and assess its effect on the overall morbidity and mortality in these patients as well as platelet functions.
Interventions
- DRUG Aspirin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2002-02 |
| Est. Completion | 2008-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00501345
The ClinicalTrials.gov registry entry for NCT00501345 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aspirin is the first listed.
NCT00501345 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00501345 about?
NCT00501345 is a clinical study titled "Aspirin in Patients With Myocardial Infarction and Thrombocytopenia". Primary Objective: To determine the risk of bleeding from ASA therapy in thrombocytopenic patients who develop Acute Coronary Syndrome (ACS), and assess its effect on the overall morbidity and mortality in these patients as well as platelet functions.
What is the current status of trial NCT00501345?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 5 participants. The study started on 2002-02. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00501345?
The interventions under investigation include: Aspirin (DRUG).
Who is sponsoring clinical trial NCT00501345?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.